← Back to Clinical Trials
Recruiting NCT06741306

NCT06741306 Comprehensive Assessment in a Longitudinal Study on Young Men Who Have Sex With Men Attracting to chemseX-2

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06741306
Status Recruiting
Phase
Sponsor Institute of HIV Research and Innovation Foundation, Thailand
Condition ChemSex Users for YMSM
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2024-03-14
Primary Completion 2027-03-31

Eligibility & Interventions

Sex Male only
Min Age 16 Years
Max Age 35 Years
Study Type OBSERVATIONAL
Interventions
Group1

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2024-03-14 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

CLYMAX is a two-phase observational study that assess multiple aspects of chemsex and young men who have sex with men (YMSM). Phase I of the study (CLYMAX,IRB No. 0695/65) was a cross-sectional descriptive study using a mixed methods data collection (focusing on qualitative data collection) assessing multiple aspects of chemsex, including the patterns of chemsex use and the perspectives on factors influencing chemsex initiation/discontinuation, effects on physical health, mental health and social outcomes, and the necessary services for a comprehensive chemsex clinic among YMSM; and the acceptability and feasibility of developing a comprehensive chemsex clinic from the perspective of YMSM, their family members or peers, and clinic staff. This phase II study (CLYMAX-2) will be a prospective cohort study using a quantitative data collection exploring the effectiveness of the implementation strategy of harm reduction models and consist of a larger number of YMSM, important baseline and follow-up information on multiple aspects of physical, psychological, and social harms.

Eligibility Criteria

Inclusion Criteria: 1. Men who have sex with men 2. Aged 16-35 years 3. Current chemsex users (defined as last chemsex used within 3 months) 4. Able to read and communicate in Thai 5. Provide informed consent Exclusion Criteria: None

Contact & Investigator

Central Contact

Nittaya Phanuphak, MD.,PhD

✉ nittaya.p@ihri.org

📞 6681 825 3544

Principal Investigator

Siriporn Nonenoy, BNH,MPH

STUDY CHAIR

Institute of HIV Research and Inovation

Frequently Asked Questions

Who can join the NCT06741306 clinical trial?

This trial is open to male participants only, aged 16 Years or older, up to 35 Years, studying ChemSex Users for YMSM. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06741306 currently recruiting?

Yes, NCT06741306 is actively recruiting participants. Contact the research team at nittaya.p@ihri.org for enrollment information.

Where is the NCT06741306 trial being conducted?

This trial is being conducted at Bangkok, Thailand, Bangkok, Thailand.

Who is sponsoring the NCT06741306 clinical trial?

NCT06741306 is sponsored by Institute of HIV Research and Innovation Foundation, Thailand. The principal investigator is Siriporn Nonenoy, BNH,MPH at Institute of HIV Research and Inovation. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology